The source records cannot be reconciled as one event: Kura Oncology reported inducement stock options for four new employees, while ORIC Pharmaceuticals reported options and restricted stock units for two new non-executive employees, with both grants dated September 1, 2026. Kura granted options for 48,450 shares at $12.89 each under its amended 2023 Inducement Option Plan; ORIC granted 39,200 non-qualified options and 6,400 restricted stock units under its 2022 Inducement Equity Incentive Plan, with the option exercise price equal to ORIC’s September 1 closing price. Both companies said their Compensation Committees approved the awards as material inducements to employment under Nasdaq Listing Rule 5635(c)(4), but the records concern separate companies and separate award packages.